Nippon India Mutual Fund entered Sun Pharmaceutical Industries with a new position of 3,31,25,559 shares, a 1.38% stake. The stake is worth ₹6,364.08 Cr at a share price of ₹1921.40 apiece.
A leading pharmaceutical manufacturer engaged in developing and marketing branded and generic formulations alongside Active Pharma Ingredients across global markets. The company operates multiple manufacturing facilities worldwide, serving customers through its extensive distribution network. Sun Pharma specializes in therapeutic areas including ophthalmology, cardiology, gastroenterology, and dermatology, combining research-driven innovation with broad-based generics production to serve patients in India and internationally.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.
